Breakeven On The Horizon For CARsgen Therapeutics Holdings Limited (HKG:2171)
CARsgen Therapeutics Holdings Limited (HKG:2171) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. The HK$6.5b market-cap company posted a loss in its most recent financial year of CN¥98m and a latest trailing-twelve-month loss of CN¥89m shrinking the gap between loss and breakeven. As path to profitability is the topic on CARsgen Therapeutics Holdings' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
CARsgen Therapeutics Holdings is bordering on breakeven, according to the 3 Hong Kong Biotechs analysts. They anticipate the company to incur a final loss in 2027, before generating positive profits of CN¥303m in 2028. Therefore, the company is expected to breakeven roughly 2 years from today. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 107%, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Underlying developments driving CARsgen Therapeutics Holdings' growth isn’t the focus of this broad overview, however, take into account that typically biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
Check out our latest analysis for CARsgen Therapeutics Holdings
One thing we’d like to point out is that The company has managed its capital judiciously, with debt making up 1.7% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.
Next Steps:
There are key fundamentals of CARsgen Therapeutics Holdings which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at CARsgen Therapeutics Holdings, take a look at CARsgen Therapeutics Holdings' company page on Simply Wall St. We've also put together a list of important aspects you should further research:
- Historical Track Record: What has CARsgen Therapeutics Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CARsgen Therapeutics Holdings' board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.